Skip to main content

Fiasp FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 7, 2020.

FDA Approved: Yes (First approved September 29, 2017)
Brand name: Fiasp
Generic name: insulin aspart
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Fiasp (insulin aspart) is a rapid-acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. Fiasp is a newer formulation of NovoLog, in which the addition of niacinamide (vitamin B3) helps to increase the speed of initial insulin absorption.

Development timeline for Fiasp

DateArticle
Jan  6, 2020Approval FDA Approves Fiasp (insulin aspart injection) for the Treatment of Children with Diabetes
Oct 22, 2019Approval FDA Approves Fiasp (insulin aspart injection) for Use in Insulin Infusion Pumps for Adults with Type 1 or Type 2 Diabetes
Sep 29, 2017Approval Novo Nordisk Receives FDA Approval for Fiasp (insulin aspart injection), a New Fast-Acting Mealtime Insulin

See also

Fiasp (insulin aspart) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer